Elena Velkoska

Level 7 Lance Townsend Building, 145 Studley Road
Heidelberg, VIC 3084, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Effect of Clazakizumab on Neutrophil-Lymphocyte Ratio in Patients Receiving Hemodialysis: Secondary Analysis of the POSIBIL6ESKD Phase 2b Trial.

Effect of Clazakizumab on Neutrophil-Lymphocyte Ratio in Patients Receiving Hemodialysis: Secondary Analysis of the POSIBIL6ESKD Phase 2b Trial.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: March 11, 2026

Plasma and Urinary Metabolomic Profiles Associated with the Salt Sensitivity of Blood Pressure in the Dietary Approaches to Stop Hypertension-Sodium Trial.

Plasma and Urinary Metabolomic Profiles Associated with the Salt Sensitivity of Blood Pressure in the Dietary Approaches to Stop Hypertension-Sodium Trial.

Journal: The Journal of nutrition

Published: September 09, 2025

Apolipoprotein A1 (CSL112) Increases Lecithin-Cholesterol Acyltransferase Levels in HDL Particles and Promotes Reverse Cholesterol Transport.

Apolipoprotein A1 (CSL112) Increases Lecithin-Cholesterol Acyltransferase Levels in HDL Particles and Promotes Reverse Cholesterol Transport.

Journal: JACC. Basic to translational science

Published: September 26, 2024

Preclinical safety and efficacy of the recombinant CR1 drug product CSL040 in rats and cynomolgus monkeys.

Preclinical safety and efficacy of the recombinant CR1 drug product CSL040 in rats and cynomolgus monkeys.

Journal: Toxicology and applied pharmacology

Published: September 25, 2024

Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Journal: Nature medicine

Published: July 03, 2024

CSL112 (Apolipoprotein A-I [Human]) Reduces the Elevation in Neutrophil-to-Lymphocyte Ratio Induced by Acute Myocardial Infarction.

CSL112 (Apolipoprotein A-I [Human]) Reduces the Elevation in Neutrophil-to-Lymphocyte Ratio Induced by Acute Myocardial Infarction.

Journal: Journal of the American Heart Association

Published: May 03, 2024

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.

Journal: Nature medicine

Published: April 04, 2024

Vascular Endothelial Growth Factor-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled Trial.

Vascular Endothelial Growth Factor-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled Trial.

Journal: Journal of the American Society of Nephrology : JASN

Published: March 12, 2024

CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Post-Myocardial Infarction.

CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Post-Myocardial Infarction.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: March 30, 2023

A method for detection of anti-drug antibodies to a biotherapeutic (CSL112) with endogenous counterpart (apolipoprotein A-I) using a novel sample pre-treatment electrochemiluminescence assay.

A method for detection of anti-drug antibodies to a biotherapeutic (CSL112) with endogenous counterpart (apolipoprotein A-I) using a novel sample pre-treatment electrochemiluminescence assay.

Journal: Journal of immunological methods

Published: May 25, 2022

Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity.

Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity.

Journal: Journal of the American Heart Association

Published: April 12, 2022

An exploratory analysis of comparative plasma metabolomic and lipidomic profiling in salt-sensitive and salt-resistant individuals from The Dietary Approaches to Stop Hypertension Sodium Trial.

An exploratory analysis of comparative plasma metabolomic and lipidomic profiling in salt-sensitive and salt-resistant individuals from The Dietary Approaches to Stop Hypertension Sodium Trial.

Journal: Journal of hypertension

Published: May 18, 2021

Showing 1-12 of 39

Last Updated: 09/26/2026